Conventus Orthopaedics said it raised $21 million out of a hoped-for $23.1 million for its shoulder and wrist fracture repair technology.
Minneapolis-based Conventus is developing a nitinol device that’s designed to expand inside the bone as an internal scaffold to prevent collapse of a shoulder fracture. Another Conventus device also uses nitinol to treat distal fractures of the radius.
Conventus raised a $24 million Series AA round in December 2014 earmarked, in part, for commercializing the FDA-cleared Conventus DRS wrist fracture device and to propel R&D for the PH shoulder repair device, which later won 510(k) clearance from the FDA.
Help employers find you! Check out all the jobs and post your resume.
Minneapolis-based Conventus is developing a nitinol device that’s designed to expand inside the bone as an internal scaffold to prevent collapse of a shoulder fracture. Another Conventus device also uses nitinol to treat distal fractures of the radius.
Conventus raised a $24 million Series AA round in December 2014 earmarked, in part, for commercializing the FDA-cleared Conventus DRS wrist fracture device and to propel R&D for the PH shoulder repair device, which later won 510(k) clearance from the FDA.
Help employers find you! Check out all the jobs and post your resume.
